Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium II

3395 - Neoadjuvant chemotherapy followed by surgery (NACT-surgery) versus concurrent cisplatin and radiation therapy (CTRT) in patients with stage IB2 to IIB squamous carcinoma of cervix: A randomized controlled trial (RCT)

Date

10 Sep 2017

Session

Presidential Symposium II

Topics

Cytotoxic Therapy;  Surgical Oncology;  Radiation Oncology;  Cervical Cancer

Presenters

Sudeep Gupta

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

S. Gupta1, P. Parab1, R. Kerkar2, U. Mahantshetty3, A. Maheshwari2, S. Sastri3, R. Engineer3, R. Hawaldar4, J. Ghosh1, S. Gulia1, S. Godbole1, N. Kumar2, J. Malliga2, R. Dalvi1, Y. Kembhavi1, M. Gaikar1, R. Ranade2, H. Tongaonkar2, R. Badwe5, S. Shrivastava3

Author affiliations

  • 1 Medical Oncology, Tata Memorial Centre, 400012 - Mumbai/IN
  • 2 Gynecologic Oncology, Tata Memorial Centre, 400012 - Mumbai/IN
  • 3 Radiation Oncology, Tata Memorial Centre, 400012 - Mumbai/IN
  • 4 Biostatistics, Tata Memorial Centre, 400012 - Mumbai/IN
  • 5 Surgical Oncology, Tata Memorial Centre, 400012 - Mumbai/IN
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3395

Background

The standard treatment for locally advanced cervical cancer is CTRT. We tested in a RCT whether outcomes could be improved by NACT-surgery.

Methods

Patients with clinical stages IB2, IIA or IIB squamous cervical cancer were randomized (stratified on stage) to either NACT-surgery arm comprising 3 cycles of paclitaxel (175 mg/m2) and carboplatin (AUC 5-6) every 3 weeks followed by radical hysterectomy or CTRT arm comprising standard pelvic radiation with 5 cycles of cisplatin (40 mg/m2) once per week. Post-operative radiation was given as per protocol criteria. Primary end point was disease-free survival (DFS, relapse or death whichever earlier) while secondary end points were overall survival (OS) and toxicity. The trial was designed to demonstrate 10% absolute increase in 5-year DFS in NACT-surgery arm, assuming 65% DFS in CTRT (control) arm (2-sided α = 0.05, power=80%) with planned sample size of 730.

Results

Trial accrual was stopped after 635 patients were randomized between September 2003 and February 2015, of whom there were 2 eligibility violations. In remaining 633 (316 NACT-surgery, 317 CTRT, intent-to-treat population) there were 113 (17.9%) IB2, 158 (25.0%) IIA and 362 (57.2%) stage IIB patients. The arms were balanced for stage, age, haemoglobin, performance status and radiological pelvic lymph node status. At time of analysis (data cut-off 30 March 2017) median follow-up was 58.5 months; number of DFS events and deaths in NACT-surgery arm were 105 and 80 and those in CTRT arm were 87 and 80, respectively. There was no significant difference between NACT-surgery and CTRT with respect to 5-year DFS (67.5% vs. 72.2%, respectively, hazard ratio [HR] = 1.299, 95% CI 0.977-1.725, P = 0.07) and 5-year OS (74.8% vs. 74.7%, respectively, HR = 1.025, 95% CI 0.752-1.398, P = 0.87). NACT-surgery was not superior to CTRT in DFS and OS after adjusting for prognostic factors. Toxicity in two arms was acceptable with some differences in pattern.

Conclusions

Neoadjuvant chemotherapy followed by radical surgery is not superior to cisplatin based concurrent chemoradiation in locally advanced squamous carcinoma of cervix.

Clinical trial identification

NCT00193739

Legal entity responsible for the study

Tata Memorial Centre

Funding

Department of Atomic Energy-Clinical Trials Unit, Tata Memorial Centre, Mumbai

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.